Antitumor efficacy was observed both in xenografts as well as in genetically engineered mouse models of colon cancer, and both in tumors with uniformly high expression of LGR5 as well in tumors with heterogeneous and low expression of LGR5, the latter reflecting more closely the situation found in human tumors. Here, LGR5 is linked to colonic neoplasm.